Sol-Gel Technologies Operating Income 2016-2024 | SLGL

Sol-Gel Technologies operating income from 2016 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Sol-Gel Technologies Annual Operating Income
(Millions of US $)
2023 $-29
2022 $-16
2021 $3
2020 $-30
2019 $-26
2018 $-34
2017 $-32
2016 $-21
2015 $-10
Sol-Gel Technologies Quarterly Operating Income
(Millions of US $)
2024-06-30 $2
2024-03-31 $-7
2023-12-31 $-5
2023-09-30 $-6
2023-06-30 $-7
2023-03-31 $-11
2022-12-31 $-6
2022-09-30 $-4
2022-06-30 $-0
2022-03-31 $-6
2021-12-31 $14
2021-09-30 $1
2021-06-30 $-8
2021-03-31 $-4
2020-12-31 $-7
2020-09-30 $-9
2020-06-30 $-8
2020-03-31 $-7
2019-12-31 $-7
2019-09-30 $-8
2019-06-30 $-5
2019-03-31 $-6
2018-12-31 $-12
2018-09-30 $-8
2018-06-30 $-7
2018-03-31 $-6
2017-12-31
2017-09-30
2017-06-30 $-6
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.012B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00